Protecting the Next Generation: What Is the Role of the Duration of Human Papillomavirus Vaccine–Related Immunity?
Author(s) -
Oliver P. Günther,
Gina Ogilvie,
Monika Naus,
Eric R. Young,
David M. Patrick,
Simon Dobson,
Bernard Duval,
PierreAndré Noël,
Fawziah Marra,
Dianne Miller,
Robert C. Brunham,
Babak Pourbohloul
Publication year - 2008
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/588140
Subject(s) - medicine , immunization , cervical cancer , vaccination , vaccine efficacy , transmission (telecommunications) , immunity , human papillomavirus , incidence (geometry) , herd immunity , epidemiology , immunology , human papillomavirus vaccine , duration (music) , disease , demography , cancer , gardasil , immune system , physics , optics , sociology , electrical engineering , engineering , art , literature
There is strong evidence that human papillomavirus (HPV) is necessary for the development of cervical cancer. A prophylactic HPV vaccine with high reported efficacy was approved in North America in 2006.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom